2023年 9月 14日
各位「Newsweek International」掲載のお知らせ
当社の子会社であるあすか製薬株式会社（東京都港区）の代表取締役社長 山口惣大が、通信社 The Worldfolio PTE. LTD.の取材を受け、米国週刊誌「Newsweek International」に当社の紹介記事が掲載されましたのでお知らせいたします。
（記事内容は添付資料をご覧ください。
）
Newsweek は、世界に約 4,600 万人の読者を持つ米国の週刊誌で、世界の文化・政治・経済・社会情勢等、あらゆる分野の情報を世界に発信、展開しています。今回、特集企画「Japanleads the way in the healthcare innovation（世界の医療をリードする日本）」に、日本企業の一社として当社を紹介したいとオファーがあり、インタビューが実現しました。
なお、インタビューの全文は、ニュースサイト「The WORLDFOLIO」に掲載されていますので、あわせてお知らせいたします。
「The WORLDFOLIO」ウェブサイト（英文）https://www.theworldfolio.com/interviews/aska-we-create-new-value-as-leading-womenshealthcare-company/5872/※記事の掲載は The Worldfolio PTE. LTD.の許可を得ています。
The Worldfolio PTE. LTD.：
20 年以上にわたって世界中の読者に高品質のコンテンツを提供してきたメディアエージェンシーです。現在は、シンガポールを拠点に、製造、不動産、建設、ヘルスケア、デジタルトランスフォーメーションなど、幅広いトピックや最新ニュースを提供しています。
以上＜お問い合わせ先＞
あすか製薬ホールディングス株式会社 グループ経営企画部 TEL：03-5484-8366

China’s Plan to Rule World’s Smart Devices

Forget Keto,Intermittent Fasting
and Ozempic.

The facts about what works—and what doesn’t—are still elusive

The Search for the Perfect Diet
08-15.09.2023
ALBANIA €6.25
AUSTRALIA $11.00
AUSTRIA €10.00BAHRAIN BD3.5
BELGIUM €7.00
CHINA RM80
CROATIA HKR70
CYPRUS €7.00

CZECH REP CZK180
DENMARK DKR57
EGYPT E£ 65.00
FINLAND €7.60
FRANCE €7.50
GERMANY €7.50
GIBRALTAR £6.05
GREECE €7.50

HOLLAND €7.00
HONG KONG HK80
HUNGARY FT1,800
IRELAND €7.00
ISRAEL NIS35
ITALY €7.00
KUWAIT KD3.00
LATVIA €6.50

LEBANON LL10,000
LITHUANIA €8.99
LUXEMBOURG €7.90
MALTA €7.00
MONTENEGRO €8.30
MOROCCO MDH70
NEW ZEALAND $14.00
NIGERIA $3.40C

NORWAY NKR119OMAN OR 3.250
POLAND PLN29.99
PORTUGAL €7.00
QATAR QR65
MALAYSIA RM27.90
ROMANIA LEI 42.00
SAUDI ARABIA SR35.00

SERBIA RSD1035
S LEONE SLL30,000
SINGAPORE $11.95
SLOVAKIA €6.50
SLOVENIA €8.50
SOUTH AFRICA R55.00
SPAIN €7.00
SWEDEN SKR119SWITZERLAND CHF10.60
UAE AED42UK £5.99
US $10.99
ZIMBABWE ZWD4.00

Original article published in Newsweek on September 1st, 2023. Written by the Worldfolio
CONTENT BY THE WORLDFOLIO

ASKA Pharmaceutical looking to be the number
one total healthcare company
With drugs for internal medicine, obstetrics and gynecology, and urology, ASKA is making sure that
all of its patients’ health needs are met.

“We create new value
as a leading women’s
healthcare company.”
Sohta Yamaguchi,President,ASKA Pharmaceutical Co., Ltd.
First established in 1920, ASKA
Pharmaceutical has grown tobecome the leading company infemale healthcare in Japan, andcurrently occupies the number one
sales position domestically in thefields of obstetrics and gynecology.
That status owes much to thegroup’s ability to adapt, and as
recently as 2021 the firm changed
its management style to a holdings
structure, enabling it to provide
a holistic service from prevention, examination and diagnosis
to treatment and post-treatment.
“ASKA Pharmaceutical Holdings Co., Ltd. has several groupcompanies,” company president
Sohta Yamaguchi explains, “andone of them focuses on pharma-

Head office in Tokyo
ceutical drugs, while another focuses on testing and equipment
for early diagnosis and prevention. With this comprehensive
approach, we can increase ourbusiness opportunities.”
One of the group’s core businesses is the production of oral
contraceptives (OCs), which, incontrast to condoms, allow womenpany in Vietnam, hoping to takeadvantage of the country’s growing economy and medical market.
Through this partnership, ASKA isaiming to establish a strong presence in Vietnam and expand into
other Asian countries from there.
Looking to the future, ASKA
has set itself a number of goals toachieve in the mid-term. “We wantto remain the leader in the field ofobstetrics and gynecology, bothin name and in reality,” says theASKA Pharmaceutical president.
“We contribute to the stablesupply of essential drugs and theelimination of unmet needs. For
example, in the thyroid disease
area, where we already have amarket share of more than 90%,
we are working on various initiatives. As well as ensuring thatthyroid patients have access toa reliable pharmaceutical supply,
we are aiming to develop drugs
that minimize the side effects
of existing drugs, or drugs that

Obstetrics and gynecology products by life stage
to assert their preference for non- seeking new collaborations overpregnancy.
seas, particularly in the fields ofBut as well as producing OCs, internal medicine, obstetrics andASKA Pharmaceutical is also ac- gynecology, and urology.
A two-pronged strategy will
tively working on developing drugs
see the company introduce uniquedrugs developed by overseas companies to the Japanese market aswell as offering licensing partnerships to overseas companies for
drugs it has developed itself.
A Relugolix combination tablet
Drugs for the treatment of thyroid called AKP-022, for instance, isdisease when launched in 1922
to minimize their side effects.
Mr. Yamaguchi again: “Weare currently in phase three ofdeveloping LF111, which utilizes
only progesterone, thus eliminating the side effects associated with estrogen.”
Treatment of dysmenorrhea isanother core focus. To this end,
ASKA has recently launched its
DroEthi combination tablets,
which, according to Mr. Yamaguchi, provide a “generic alternative to a well-established product Total healthcare company with a strong foundation as a specialty
pharma company
already on the market.”
While initial feedback has been set to go to clinical trials in July treat thyroid disease with a difgood, it is only one in a range of 2023. Focusing on uterine fibroids ferent approach,” Mr. Yamaguchi
products the company offers in in females, the product is being explains. “Through this we will
this particular field. “One of ourpositioned as the successor respond to medical needs thatstrengths,” Mr. Yamaguchi
to RELUMINA, and is have previously not been met.”
explains, “is that we proexpected to enable
Through its provision of drugs
longer durations of and treatments as well as medicalvide a number of prodadministration, and equipment and related services,
ucts for dysmenorrhea
therefore improve the ultimate aim, Mr. Yamagutreatment, a field inpatient convenience. chi states, is “to become a total
which we hold aroundIn 2021, mean- healthcare company and a global
a 50% market share.”
And indeed, having
while, the company company, offering comprehensive
long conducted R&D
invested in a partner- health services for females.”both in-house andship with Ha Tay
with other companies, Three core areas with a P h a r m a c e u t i c a l
ASKA is now actively focus on pharmaceuticals Joint Stock Comwww.aska-pharma.co.jp